Welcome to the Precipio Q2 2026 Shareholder Update Conference Call. All participants will be in a lesson-only mode. Should you need assistance, please signal a conference specialist by pressing the star key 4 by 0. Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current expectations Forecasts and Assumptions and Asserts Significant Risks and Uncertainties His statements may be identified by words such as may, will, should, give, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue, or the negative of these terms or other words or terms of similar meaning. Risks and Uncertainties that could cause our actual results to differ materially from those set forth in any forward-looking statements include, but are not limited to, the merits listed under the risk factors in our annual report on Form 3K for the year ended December 31, 2025, which is on file with the Securities and Exchange Commission, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. The following statements and information, including forward-looking statements, speak only to the date they are provided and we do not undertake any obligation to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events, or otherwise except as required by law. Now, let me hand the call over to Ilan Danieli, Principio CEO. Please go ahead.

Good afternoon, everyone, and thank you for joining us for Precipio's second quarter 2026 shareholder update call. On the call today, I'm going to walk through our second quarter results, provide some additional context around what drove the quarter, discuss what we're seeing across our pathology and product businesses, and then talk about what we can expect as we move into the second half of the year. After our prepared remarks, we'll open the call for questions. I'd like to start by putting this quarter's results into perspective. Three months ago, when we discussed Q1, we explained that despite relatively flat revenue and a small cash fund, we believe the underlying business remains strong. We talked about the timing of shipping orders to customers and how that impacted quarterly revenue numbers. We also talked about the normal seasonality in the early part of the calendar year in terms of cash collection. And most importantly, we talked about the commercial pipeline we're building and our expectations that the numbers will demonstrate that the business continues its momentum as we move through the year. I think our two numbers did exactly that. For the first time in Scipio's history, quarterly revenues surpassed $7 million. We returned a positive adjusted EBITDA. We generated approximately $700,000 in operating cash flow. And we ended the quarter with more than $3 million cash in the bank with an increase of half a million in cash in just this quarter. What I think is particularly important is we achieved that cash position organically without raising capital. Pro, when I look at Q2, I don't think we see it this quarter. I see another important validation of the operating model we've spent years building. To formally review the quarterly numbers, I'd like to take a moment to discuss our key strategic advantage in the market, as we've described Precipio in the past as having a unique flyway. Our laboratory enables us to identify problems in the process of diagnosing cancer. Thank you very much. One way I like to explain why this is intended is that most diagnostic companies develop a product and then try to recreate the use of the product in a clinical laboratory. They come up with a scientific concept and then try to apply that concept to create a product they believe will have demand in the market. And that doesn't always happen for various reasons ranging from clinical utility to workflow to regulatory or due to billing or economic hurdles. Our model is different. Our clinical experience drives product development because we already have the clinical laboratory. We experience the problems firsthand. We then develop solutions to those problems. We use those solutions ourselves in our labs to improve outcomes for the patient samples that arrive to our labs daily, while demonstrating clinical, operational, and economic value. And when all the boxes are checked, we begin the process of taking those products outside of our four walls. The products are then offered to other laboratories, our customers, which results in them delivering an impact on patients far beyond the recipient's own laboratory footprint. The lab division isn't simply a service business, and the product division isn't simply a manufacturing business. They reinforce one another, and that is our flywheel. That expands our addressable market without requiring us to build another participatory laboratory every time we want to enter a new geography or reach another customer. And as our product business moves, it creates a more scalable revenue stream alongside our core pathology operations. QQ is a good example of our unique model where both divisions are working together simultaneously. A great example of where this model is particularly relevant is AML, or Acute Myeloid Leukemia. Our approach has always been to identify diagnostic problems where we can create a solution that can have a meaningful impact on patient care. AML is a great example because treatment decisions can be extremely time critical. The A in AML stands for acute, which indeed AML patients are at immediate risk of dying, sometimes within 48 hours. In reality, where time-critical molecular laboratory results are delivered on average in 10 to 14 days, the diagnostic market systematically fails the clinical needs of the patient. Our rapid AML delivers that critical information in one day, ensuring that the patient is placed on the appropriate therapy in a timeframe that aligns with the urgent clinical situation the patient faces. This is not a theoretical exercise either. Every week, we receive several patient samples that are diagnosed with AML in our lab, and we observe firsthand the impact of our lab's living room's results the same day in a speed that meets the clinician's needs to take care of their patients. Our ability to develop and clinically validate solutions within our own laboratory gives us an advantage in bringing products to market that address true clinical problems faced by laboratories and clinicians. And just of importance, once we've validated those solutions internally, the product business gives us the opportunity to scale them beyond the patients who come through to their own laboratories. That's how we think about the relationship between innovation, patient impact, scaling the business, and shareable disparities. This aspect in particular has garnered quite a bit of interest within numerous customers, both domestically and internationally. In addition to actual sales, we're working on several substantial marketing collaborations, as well as clinical study initiatives that will call attention to the problem, as well as product solutions front and center. Supplementing the sales effort with these marketing initiatives is a crucial element within the biotech world. In the past, we did not have the resources to drive these initiatives, but we do now, and I'm looking forward to sharing some of those initiatives in the near future. Now, let's look at the numbers starting with revenue. Revenue for Q2 exceeded $7 million compared with the cost of $6.7 million in Q1. Perhaps more importantly, revenue increased approximately 22% year-over-year from $5.7 million in the same quarter of 2025. So, we're seeing both sequential quarter and year-over-year growth. Breaking down those numbers, our pathology business generated approximately $6.1 million in revenue compared to $6 million in Q1. This is a modest increase, but keep in mind that, as we said before, our resources are focused on the commercial growth of our products. and, indeed, our product business generated approximately $900,000 compared with approximately $660,000 in the prior quarter, up 35%. Now, that's an important number. Our previous quarter record for product revenue was approximately $750,000, which happened in Q4 of last year, or two quarters ago. So Q2 was approximately 21% above our previous record. Now, I want to take a moment to connect this back to something we discussed last quarter. In Q1, we explained that one of our larger customers had moved the shipment that was expected at the end of March into early April. We emphasized back then that this was a timing issue, not a lot of a customer, and not a change in any underlying demand. Q2 gives us an opportunity to see that distinction more clearly. Incuratively, we all know that a business is an ongoing, breathing entity, and that the division into quarters is an arbitrary cutoff, a mark in the sand, that doesn't always coincide with the organic movement of the business. Quarter-to-quarter timing will always create some variability, particularly in our product business. That's why I believe it's important to look beyond any individual quarter and focus on the positive trajectory of the business. I'd like to spend a few moments on products because I think this is the more important development of the quarter. Alongside the 21 votes from our previous record high, what is equally encouraging is the continued growth of our pipeline. During Q2, our commercial team added approximately 10 new distributed reps to the team they are working with. This opens the door to more territories and more potential customers. We've also identified over 25 new qualified customers and have over 30 meetings either being scheduled or already completed during the second quarter with those new customers. All that builds into a further increase to our pipeline. One of the challenges we discussed in the past is figuring out the recipe for how to work with each of these distributors. We have distribution partnerships with Dillman Fisher, McKesson, Medline, and Cardinal, which basically covers the entire department market. Many investors have asked, why does business have taken so long to ramp up, and why, for a period of time, revenue was relatively flat? We discussed the hiring of a new commercial team that started at the beginning of this year, and that's a key factor in having a capable team that can go out and sell. But the other factor is developing working relationships with our distributors. We know that with these four distributors, we have total coverage of the market. And each of these are huge organizations that operate very differently. Their sales team are structured differently, their ways of interacting with vendors are different, and their incentives vary from one organization to the other. It's not a one-size-fits-all. I give kudos to our commercial team, who are making progress in figuring out those unique recipes for each distributor, and the results show a significant increase to our pipeline. In the second half of the year, I expect to see a start of moving those accounts from pipeline to active, with corresponding revenues making significant contributions to our growth. Moving to our pathology division, revenue increased to approximately $6.1 million from $6 million in Q1. While this sequential increase is modest, it's important to remember the goals given to the division, as we've recently described it as a critical part of Scipio's flywheel. The main purpose is the generation of recurring revenue and cash flow, but more importantly, the provision of the clinical infrastructure behind our product development strategies. We therefore believe that this division will continue to grow organically and continue to fill its purpose for the overall business. Turning to profitability, adjusted even value was approximately $400,000 in Q2, and potentially negative $200,000 in Q1. That's an approximate $600,000 swing from quarter to quarter. There are two primary items that contribute to that change. First, revenue increased by approximately $300,000, and second, stock-based compensation expense decreased by approximately $200,000. I think the broader takeaway is more important than any individual expense slide item. As revenue grows, we have the opportunity to leverage the infrastructure we've already built. Future provides another example of that operating leverage. There's a meaningful difference between buying growth with significant spending and scaling up using the infrastructure we've already built. We've spent years building the laboratory, developing our product, establishing the commercial infrastructure, and putting the people and systems in place. and we grow revenue on that platform, we expect more of the incremental revenue to make it great through down to the PLL. And that brings me to perhaps the most important number in this quarter's results, cash. We've generated approximately 700,000 in cash flow operations due to Q2, which is 10% of quarterly top line number. That's an impressive achievement, particularly at our modest revenue numbers in our size. Total cash increase of approximately half a million dollars in the end of Q2 was more than $3 million cash in the bank. For comparison, our cash balance in the end of Q2 of last year was approximately 1.1 million. I want to emphasize something important here. That increase didn't come from a financing event. It came from business operations. For a company in our stage and in our sector, that's an important distinction. Emerging growth companies, and particularly in diagnostics and biotech, typically need to repeatedly return to the capital markets to fund their growth. Our approach is different. We've worked hard to build a business that can fund an increasing portion of its growth through its own operations. Generating some of the 100,000 of operating cash while simultaneously building a business is an important indication of what this model can potentially produce as we continue to scale. Moving to the second half of 2026, what should shareholders be watching for as we move into the second half? First, we expect continued revenue growth. We've now crossed the $70 million quarterly threshold. Our focus is on building from here on. Second, products revenue growth. Reaching approximately $900,000 in quarterly product revenue is an important achievement, and we'll continue working to expand the customer base and commercial reach of that business. Third, commercial pipeline conversions. We've invested and will continue to invest in expanding our sales capacity as we expect opportunities generated through those investments to increasingly translate into revenue. Fourth, operating leverage. As revenue grows, we'll continue focusing on translating that growth into adjusted EBITDA and ultimately cash generation. I'll end with this. Three months ago, we asked shareholders to look beyond a relatively flat Q1 and focus on what was happening beneath the headline numbers. Q2 shows why. Quarterly revenue, and specifically product revenue, reached a company record, while the business generated solid adjusted EBITDA and cash flow. Those are meaningful financial milestones that are a result of a strong business and commercial operations. but we're not looking at them as an endpoint. We view them as evidence that the model we've built is beginning to demonstrate the operating leverage and cash generation potential we've been working towards. Our focus now is execution. We need to continue to both build and convert the product's commercial pipeline. We need to continue to innovate, creating new products that deliver better patient care and provide better value to our customers. I'm willing to demonstrate the continued translation of revenue growth into EBITDA and cash flow, which ultimately drives shareholder value. I think we're entering the second half of 2026 in a stronger position than we've ever been in, and we're excited about the opportunities ahead. Thank you again to your continued support and for joining us today. And with that, we'll open the call to questions.

Thank you. Ladies and gentlemen, we will now begin the question and answer session. Should you have a question, please press star 4 by the 1 on your telephone keypad. You will hear a prompt that your hand has been raised, and should you wish to cancel your request, please press star 4 by the 2. If you are using a speakerphone, please lift the handset before pressing any keys. Thank you. And the first question comes from the line of Adam Hart from Reviticus Partners. Please go ahead.

Hi, guys. Congratulations on a fine quarter. My question is, can you guys offer any commentary at all on the unusually high trading last month when we traded about 800,000 shares in a two-day period, where those shares came from? How on earth did it do that? Are you guys on top of that at all? Yeah, hey, Adam. Thanks for the call.

Honestly, I wish there was more transparency from our end into that. You know, we probably would, with the Bloomberg terminal, see more than we do. So, you know, it's as surprising to me as it is to you. I think we're starting to see the fruits of some of the, you know, more IR activities that we're doing, participating in investment conferences. You know, we had a great event at the MicroCat Conference in Vegas in June, I think. So I think, you know, word is starting to spread just like we planned after we came out at the beginning of the year. I think there's more and more tension that's being caught by us. The other factor, of course, as you know, is computer algo trading, which is very hard to trace and very hard to explain.

Sure. All right. Thank you, guys. Yeah. Thank you.

Thank you. Once again, should you have a question, please press star four by the one on your telephone keyboard. Once again, press star and one to ask a question. No further questions at this time. Mr. Danieli, please proceed.

Yeah, I just wanted to thank everyone for joining and our community support. Have a nice evening, everyone. Thank you.

This concludes today's call. Thank you for participating in the All This Connects.